Clinical Trial Results

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

PHASE3INTERVENTIONAL Anniston, Alabama +4 more

RECRUITING

The Anifrolumab PRIM Program

N/AOBSERVATIONAL Södertälje +4 more

RECRUITING

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

PHASE1, PHASE2INTERVENTIONAL San Francisco, California +4 more

RECRUITING

Anifrolumab Pregnancy Study

N/AOBSERVATIONAL Cary, North Carolina +4 more

RECRUITING

A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus

PHASE2INTERVENTIONAL Bengbu, Anhui +4 more

RECRUITING

The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases

PHASE1INTERVENTIONAL Nanjing, Jiangsu +4 more

RECRUITING

Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN

N/AOBSERVATIONAL Charlotte, North Carolina +4 more

RECRUITING

A Study of E6742 in Participants With Systemic Lupus Erythematosus

PHASE2INTERVENTIONAL Beijing, Beijing Municipality +4 more

RECRUITING

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

PHASE1INTERVENTIONAL Los Angeles, California +4 more

RECRUITING

Immun4Cure Cohort of Autoimmune Diseases

N/AOBSERVATIONAL Montpellier +4 more

RECRUITING

MTS109 in Patients With Refractory Autoimmune Diseases

EARLY_PHASE1INTERVENTIONAL Shanghai, Shanghai Municipality +4 more

RECRUITING

A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus

PHASE1, PHASE2INTERVENTIONAL Beijing +4 more

RECRUITING

Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus

EARLY_PHASE1INTERVENTIONAL Nanjing, Jiangsu +4 more

RECRUITING

Biomarker Development for Autoimmune Disorders Involving the Kidneys

N/AOBSERVATIONAL Oslo, Oslo +4 more

RECRUITING

Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE)

N/AOBSERVATIONAL Bucharest +4 more

RECRUITING

Follow-up of the Systemic Lupus Erythematosus Cohort as Part of the Multidisciplinary Consultation at Brest CHRU

N/AOBSERVATIONAL Brest +4 more

RECRUITING

Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users

N/AOBSERVATIONAL Las Vegas, Nevada +4 more

RECRUITING

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

PHASE2INTERVENTIONAL Scottsdale, Arizona +4 more

RECRUITING

NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care

N/AOBSERVATIONAL Bad Bramstedt +4 more

RECRUITING

A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)

PHASE1INTERVENTIONAL Fukuoka +4 more

RECRUITING

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

PHASE1INTERVENTIONAL Cambridge, Arizona +4 more

RECRUITING

Anifrolumab Malignancy and Serious Infections Study

N/AOBSERVATIONAL Copenhagen +4 more

RECRUITING

Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia

PHASE2, PHASE3INTERVENTIONAL Beijing, Beijing Municipality +4 more

RECRUITING

LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus

NAINTERVENTIONAL Freiburg, Baden Wurttemberg +4 more

RECRUITING

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

PHASE1, PHASE2INTERVENTIONAL Philadelphia, Pennsylvania +4 more

RECRUITING